Respiratory medicine
-
Respiratory medicine · Jan 2019
Randomized Controlled Trial Comparative StudyLung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.
In the INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing of disease progression. We characterised the effects of nintedanib on physiologic outcomes using pooled data from the INPULSIS® trials. ⋯ A range of physiologic outcome measures in the INPULSIS® trials support the effect of nintedanib on reducing disease progression in patients with IPF.
-
Respiratory medicine · Jan 2019
Combined pulmonary fibrosis and emphysema as a clinicoradiologic entity: Characterization of presenting lung fibrosis and implications for survival.
The prevalence of classifiable and unclassifiable causes of lung fibrosis and its implications for survival are mostly unknown in combined pulmonary fibrosis and emphysema (CPFE). ⋯ Our findings suggest only about a third of CPFE patients represent suspected UIP/IPF; the majority were clinically and radiologically unclassifiable ILD whose survival was comparatively better. Identifiable or secondary causes of lung fibrosis in CPFE occurred in about a fifth of presenting patients.
-
Respiratory medicine · Jan 2019
Multicenter Study Comparative StudyRestrictive spirometry pattern is associated with low physical activity levels. A population based international study.
Restrictive spirometry pattern is an under-recognised disorder with a poor morbidity and mortality prognosis. We compared physical activity levels between adults with a restrictive spirometry pattern and with normal spirometry. ⋯ Adults with a restrictive spirometry pattern were more likely to report low levels of physical activity than those with normal spirometry. These results highlight the need to identify and act on this understudied but prevalent condition.
-
Respiratory medicine · Jan 2019
Possible role of airway microvascular permeability on airway obstruction in patients with chronic obstructive pulmonary disease.
Airway microvascular system participates in the airway inflammation that is central to the pathophysiology of inflammatory lung disorders. ⋯ Airway microvascular permeability in the peripheral airways is increased in patients with COPD, and is associated with the severity of airway obstruction. We may need to consider this characteristic feature as a target in any therapeutic strategy for the treatment of the disease. (237 words).